Contrad Swiss is a dynamic Swiss-based pharmaceutical corporation leading the revolution in regenerative medicine. The company is the owner of SIGMOLECS Technology, which significantly advances the current use of peptides as active ingredients. This unique technology communicates with cells in their own language, enabling more effective therapies across a wide range of treatments. Contrad Swiss offers a diverse portfolio that includes medical devices and aesthetic products, all manufactured in EU and Swiss facilities. Positioned within the premium segment, they deliver unmatched value to their clients in the pharmaceutical industry.

Services include:
- Finished Dosage Forms
- Medical Devices
- Aesthetic Products

Contrad Swiss SA is committed to innovation and excellence in the pharmaceutical sector, providing top-tier products and services tailored to meet the needs of the industry. For further information, please visit contrad.ch.